Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yes a very good article and a must read! This has been happening here in the last couple years and it does not look like they are going to stop! I re-posted the article you found Lunatick on a few other boards!
Caladrius Announces Research Collaboration with the University of Southern California and California Institute of Technology
Collaboration will explore next-generation strategies for Caladrius' core cancer technology
New York, NY (June 18, 2015) - Caladrius Biosciences, Inc. (NASDAQ:CLBS), ("Caladrius" or the "Company", formerly NeoStem, Inc.), a cell therapy leader with a late-stage clinical program for immuno-oncology, announced today that it has entered into a material transfer agreement with the University of Southern California and the California Institute of Technology, concerning next-generation strategies for its core cancer technology.
This research collaboration will build on Caladrius' highly successful manufacturing protocol for its lead cancer program, CLBS20 (aka NBS20), by exploring techniques to further enhance the isolation of cancer initiating cells with the goal of increasing the number of cancer patients that might benefit from treatment.
CLBS20 is the subject of a Phase 3 clinical trial investigating its efficacy in the treatment of late-stage melanoma, the Intus Study. The trial has been granted a Special Protocol Assessment by the US Food and Drug Administration (FDA) and the CLBS20 development program has been granted Orphan Drug and Fast Track designations by FDA. Randomization of the first patient in the Intus trial occurred in April 2015.
"This collaboration illustrates Caladrius' continued commitment to the optimization of our technologies through association with two prominent research universities," said Dr. David J. Mazzo, Caladrius' Chief Executive Officer.
Advanced melanoma is exceedingly difficult to treat, with a five-year survival rate of approximately 15%. There are 20,000 estimated new cases, and an estimated 10,000 deaths, from metastatic melanoma each year in the United States. The US melanoma market is approximately $1 billion per year, which is predominantly spent to treat metastatic melanoma. The platform on which CLBS20 is based is potentially applicable across multiple solid tumor types, including lung, colon and ovarian cancer, hepatocellular carcinoma and glioblastoma multiforme.
CLBS20 uses the patient's own immune cells and tumor-initiating cells to create an immunotherapy therapeutic vaccine. It is unique in targeting these cancer- or tumor-initiating cells; other therapies, which target different tumor cells, may treat existing cancer but may not be as likely to prevent tumor recurrence.
For more information on the Intus Study, which will be enrolling at approximately 50 sites across the US, Canada, Australia and New Zealand, please visit www.theintusstudy.com or www.clinicaltrials.gov/ct2/show/NCT01875653.
About Caladrius Biosciences, Inc. (formerly NeoStem, Inc.)
Caladrius Biosciences, Inc. is among the first of a new breed of immunotherapy companies with proven expertise and unique experience in cell process optimization, development, and manufacturing. Caladrius is a cell therapy leader with late-stage clinical programs based on a proprietary platform technology for immuno-oncology, as well as additional platform technologies for ischemic repair and immunomodulation, and capabilities that support other cell therapy developers. This integrated approach supports the industry in bringing significant life-improving medical treatments to market. www.caladrius.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, the Company's ability to develop and grow its business, the successful development of cellular therapies with respect to the Company's research and development and clinical evaluation efforts in connection with the Company's Immuno-Oncology Program, Ischemic Repair Program, Immune Modulation Program and other cell therapies, the future of the regenerative medicine industry and the role of stem cells and cellular therapy in that industry, and the performance and planned expansion of the Company's wholly-owned subsidiary and its center of excellence for cell therapy process development, engineering and manufacturing, PCT. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see the factors described under the heading, "Item 1A. Risk Factors" in the Company's Annual Report on Form 10-K filed with the SEC on March 2, 2015 and those described in the Company's other periodic filings with the SEC. The Company undertakes no obligation to update or revise any forward-looking statements.
This is true and it eats at me! When the results from NBS10 came out AF from the street came out and said the outcome for the trial was changed midstream to meet the results! The outcome was changed but not to meet the results but what the FDA considered a good measuring point and it was done before the trials end! This brought the stock down fast and everybody started bailing! The problem I thought was old management, When they changed the endpoint they should have made this public and explained why but they did not. When the results came out and AF made his statement they did not reply or say a thing for 3 or 4 days which it was to late by then! They should have published the outcome was being change before hand and when the statements where made they should have had a press release that day backing up what HAPPENED. PEOPLE DONT REALISE THINGS THEY LEARN IN TRIALS CHANGE AND UPDATE THE TRIALS ALL THE TIME! I own GILD also a bigger pharm and they have changed what the outcome is going to be also, all pharms have done this.
Thank You so very much! I would pump the hell out of this stock if I could morally! But when posting it is only fair to post both and let the people do there own DD and invest accordingly. I only feel that if I have found it I should share it, positive or not!
Evidently you do not read my post! I own so much of this stock and again YES I BELIEVE IN THE COMPANY!! My reply was to somebody that said the slides look familiar! I was telling them that those slides will not change until we have results and that is true! Of course we have a lot coming with Japan and hopefully partnerships! If you look at the NBS10 presentation they gave the same one about 5times in a couple months because nothing had changed in the trial! The Intus study presentation will be given about 5 more times if not more at different events BUT the presentation and the slides will be the same till new results!
The slides look familiar because they are the same ones on there site! The presentations they will be giving are going to be the same until something new happens or results come in which will not be for a while! Other than the start of Phase 3 there is no new news yet. Pardon the language but I can not hear shit on that audio!
What did it say on the Russell? I went there and can not find additions or deletions?? Could you copy and paste what it says please? Thank You
I can not believe this price at all! I add a few thousand more at $2.68 and a few more thousand when it hit $2.06 before! I was actually hoping the PPS would start rising. I do not know why every time we have good news the PPS goes down! Yes this is a really good price but I wish they would take the sale sign down already! LOL
ImmunoCellular Therapeutics Enters into Manufacturing Agreement with PCT LLC, a Caladrius Company, for US Production of ICT-107 for Phase 3 Registration Trial
.
LOS ANGELES, June 15, 2015 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) announced the selection of PCT, LLC, a subsidiary of Caladrius Biosciences, Inc. ("Caladrius") (NASDAQ: CLBS), as the US manufacturer for ImmunoCellular's ICT-107 phase 3 registrational clinical program in newly diagnosed glioblastoma, anticipated to begin in the second half of 2015. Under the terms of the multi-year agreement, PCT will provide current good manufacturing practice (cGMP) services for the manufacture of clinical supplies of ICT-107, a dendritic cell-based immunotherapy targeting six tumor-associated antigens. PCT, which was previously engaged by ImmunoCellular to manufacture clinical supplies of ICT-107 and the Company's other cancer immunotherapy clinical programs, is also working with ImmunoCellular's European contract manufacturer, PharmaCell B.V., to perform a technology transfer process to harmonize the EU and US methods of production of ICT-107 for the planned phase 3 registration trial. PCT's facilities are registered with the FDA as human cells, tissues, and cellular and tissue-based products (HCT/Ps) facilities, and maintain GMP-compliant quality systems.
"Selecting our US manufacturer for the ICT-107 phase 3 trial is an important step toward initiation of our registration program," said Andrew Gengos, ImmunoCellular Chief Executive Officer. "We have been pleased with PCT's ability to provide high quality, cost-effective and consistent manufacturing, and have confidence in their ability to support our phase 3 trial. Over the coming weeks, we look forward to announcing additional key milestones toward initiating the phase 3 trial, which have the potential to be major value-creating events for our Company. We expect to be in position to begin patient enrollment in the late third quarter or early fourth quarter of this year."
"We are extremely pleased that the leadership team at ImmunoCellular has chosen to develop a long-term relationship partnership with PCT in order to maintain the cell therapy manufacturing reliability, quality, and cost efficiencies they have come to expect," said Dr. Robert A. Preti, President of PCT, and Chief Technology Officer of Caladrius. "We feel our clients significantly reduce their clinical development risk by manufacturing with PCT and leveraging our Innovation and Quality infrastructure."
About ImmunoCellular Therapeutics, Ltd.
ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. ImmunoCellular has concluded a phase 2 trial of its lead product candidate, ICT-107, a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. ImmunoCellular's pipeline also includes: ICT-121, a dendritic cell immunotherapy targeting the CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a dendritic cell immunotherapy targeting antigens on ovarian cancer stem cells; and the Stem-to-T-cell research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer-killing T-cells. To learn more about ImmunoCellular, please visit www.imuc.com.
About Caladrius Biosciences, Inc. (formerly NeoStem, Inc.)
Caladrius Biosciences, Inc. is among the first of a new breed of immunotherapy companies with proven expertise and unique experience in cell process optimization, development, and manufacturing. Caladrius is a cell therapy leader with late-stage clinical programs based on a proprietary platform technology for immuno-oncology, as well as additional platform technologies for ischemic repair and immunomodulation, and capabilities that support other cell therapy developers. This integrated approach supports the industry in bringing significant life-improving medical treatments to market. To learn more about Caladrius, please visit www.caladrius.com.
Forward-Looking Statements for ImmunoCellular Therapeutics
This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties, including the risk that ICT-107 can be further successfully manufactured, developed or commercialized. Additional risks and uncertainties are described in IMUC's most recently filed quarterly report on Form 10-Q and annual report on Form 10-K. Except as required by law, IMUC undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
For ImmunoCellular Therapeutics, Ltd.
Jane Green
Investor Relations
415.348.0010
jane@jmgcomm.com
Logo - http://photos.prnewswire.com/prnh/20140109/AQ43875LOGO
PCT, a Caladrius Company, Expands Relationship with ImmunoCellular Therapeutics to Provide Manufacturing For Their Phase 3 Trial
New York (June 15, 2015) - Caladrius Biosciences, Inc. (Nasdaq:CLBS) ("Caladrius"), a cell therapy leader with a late-stage clinical program for immuno-oncology, announced today a new Agreement between its wholly-owned subsidiary, PCT, LLC, a Caladrius Company ("PCT"), and ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT:IMUC), a clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers.
Under this Agreement, PCT will produce ICT-107, a dendritic cell-based immunotherapy targeting six glioblastoma tumor-associated antigens, for a pivotal Phase 3 trial in patients with newly diagnosed glioblastoma. PCT has served as an external manufacturing and development provider for ImmunoCellular since 2011, including clinical production for ImmunoCellular's ICT-107 Phase 2 trial.
PCT will provide manufacturing services, including processing, packaging, labelling, quality control testing, release, shipping and storage, as well as process requalification, for ICT-107. The agreement includes the provision of a semi-dedicated controlled environment room and staff to meet ImmunoCellular's Phase 3 manufacturing needs. Furthermore, ImmunoCellular will make use of PCT's capability to perform a technology transfer process to harmonize the EU and US methods of production of ICT-107.
"Ensuring that ImmunoCellular has US manufacturing capacity that can fully support our ICT-107 phase 3 registration program, and potentially include commercial manufacturing, is an important step toward initiation of our Phase 3 registration program," said Andrew Gengos, ImmunoCellular Chief Executive Officer.
"We are extremely pleased that the leadership team at ImmunoCellular, like a number of our clients, has chosen to develop a long-term relationship partnership with PCT in order to maintain the cell therapy manufacturing reliability, quality, and cost efficiencies they have come to expect," said Dr. Robert A. Preti, President of PCT, and Chief Technology Officer of Caladrius. "We feel our clients significantly reduce their clinical development risk by manufacturing with PCT and leveraging our Innovation and Quality infrastructure."
About Caladrius Biosciences, Inc. (formerly NeoStem, Inc.)
Caladrius Biosciences, Inc. is among the first of a new breed of immunotherapy companies with proven expertise and unique experience in cell process optimization, development, and manufacturing. Caladrius is a cell therapy leader with late-stage clinical programs based on a proprietary platform technology for immuno-oncology, as well as additional platform technologies for ischemic repair and immunomodulation, and capabilities that support other cell therapy developers. This integrated approach supports the industry in bringing significant life-improving medical treatments to market. www.caladrius.com
About ImmunoCellular Therapeutics, Ltd.
ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical stage company that is developing immune-based therapies for the treatment of brain and other cancers. ImmunoCellular has concluded a phase 2 trial of its lead product candidate, ICT-107, a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. ImmunoCellular's pipeline also includes: ICT-121, a dendritic cell immunotherapy targeting the CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a dendritic cell immunotherapy targeting antigens on ovarian cancer stem cells; and the Stem-to-T-cell research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer-killing T-cells. To learn more about ImmunoCellular, please visit www.imuc.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the timing and success of the proposed public offering. Caladrius' actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include, among others, the uncertainties related to market conditions, the completion of the public offering on the anticipated terms or at all, the final terms of the proposed offering, and the satisfaction of customary closing conditions related to the proposed public offering. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Caladrius in general, see the factors described under the heading, "Item 1A. Risk Factors" in Caladrius' Annual Report on Form 10-K filed with the SEC on March 2, 2015 and those described in Caladrius' other periodic filings with the SEC. Caladrius undertakes no obligation to update or revise any forward-looking statements.
It never hurts to repost a good article like this! Not everybody probably seen it and for those that did it is a reminder of how good this science is!!!
Cancer survival rates>>> From the earlier Phase 2 trial, there was a 50% 5 year survival rate, meaning half of the patients treated were still alive at 5 years from treatment. From a later Phase 2 trial there was a 72% 2 year survival rate.
So it is
50% FOR 5 YEARS VERSUS 15%
72% FOR 2 YEARS VERSUS 25%
YOU ASK ME THEY ARE BOTH GOOD! Especially if your in the group that makes it!
MY PPS! Sorry I should have stated that!
Yes it is impressive! Since the other statics suggest there is only a 10 to 15% survival rate!
This is what I have talked about before! For some reason every time we should be going a step up we end up going backwards! If you look at the charts for today at around 1 this stock took a 10cent drop straight down and never recovered! Why a 10 cent drop for no reason??? It happens all the time, I honestly believe the stock is being manipulated, BUT why???
I also talked to Eric Powers from NBS about the results so far and this is his answer::
Debbie,
We received your inquiry to Caladrius (formerly NeoStem). You asked about how many participants in the Phase 1 and Phase 2 trials from our product candidate (CLBS20, also known as NBS20) are still alive. The Phase 2 trials are the applicable ones as both used a product comparable to our Phase 3 product candidate. From the earlier Phase 2 trial, there was a 50% 5 year survival rate, meaning half of the patients treated were still alive at 5 years from treatment. From a later Phase 2 trial there was a 72% 2 year survival rate.
I do not have the numbers of exact patients still alive but I hope this helps.
Eric Powers
With these kind of results we should be pushing 5 to 7 PPS with no questions!
Cancer Special Report: Body, heal thyself
06-08-2015
by Randall C Willis
http://www.ddn-news.com/index.php?pg=77&articleid=9609
This is not my post BUT taken from another board(just so you don't think I am this smart LOL)
I need to post this here so you can understand the value of NBS and why I have stuck with it 3 years even if I am way down on the stock(I do believe in the science)
Reading this first:
FDA panel gives a thumbs up to Amgen's T-Vec for melanoma http://www.fiercebiotech.com/story/fda-panel-gives-amgen-thumbs-t-vec-melanoma/2015-04-29
What you just read is valued at $1Billion Dollars!(The company that sold the technology got 1 billion for it. You probably have heard of T-VEC.)
Now here is the comparison of there treatment and NBS20
T-VEC Phase 2:
Overall survival was 54% at 1 year and 52% at 2 years—demonstrating that responses to T-VEC are quite durable.
T-VEC Phase 3 interim: Median survival of 23.3 Months
NBS20 Phase 2:
At two years, survival was 72% compared to 31% for control patients (p=0.007), which was consistent with the previous Phase 2 trial’s findings in which NBS20 demonstrated 73% two-year survival in 54 patients, with a median survival of 60 months.
If this does not tell you what a deal NBS is or should I say CLBS is I do not know what to say!
I thought this one would change over. I have no idea what are how it has to be done.
No I go there and read, I belong to a lot of boards. I am retired and have all day to read lol, I basically live off what I make on the stocks right now. I retired at 42 and am now 59, I do get a retirement check but what I make on the stocks is pretty much the same amount so it makes it nice.
I believe the same basically as you, hoping for that $2.50 range. I have read the one story of the man that is cured. I would like them to put out some kind of number on how many of the people that have been treated since 2009 that are cured or alive. I think this would raise the stock tremendously!
I a honestly hoping with the new name maybe a quarter up! Understand I have held this stock 3 years and will not let go of it! I am not putting it down especially at these prices it is a steal, I totally believe in the science and the people they have now! I have just found it better to post good and bad no matter what. I think people get the idea sometimes I am a basher BUT if you are investing your hard earned money I feel it is only fair you know the truth so I post what I know good and bad.
What is your guess on the weeks end??
OK sec filings are in and dated JUNE 4>> http://www.nasdaq.com/symbol/nbs/sec-filings
If you read all the sec filings you will find they where shares GIVEN OUT not BOUGHT !
Just read down past the box and on each one of them you will see this...
Explanation of Responses:
( 1) On June 2, 2015 (the "Grant Date"), the Reporting Person was granted an award of 40,000 shares of the Company's common stock (the "Shares"), subject to all of the terms and conditions of the Company's 2009 Equity Compensation Plan (the "Plan"). The Shares vest as follows: as to 25% of the shares on the Grant Date, and the remaining 75% shall vest quarterly over a period of thirty-six months from the Grant Date. With regard to the Shares, the Company agreed to pay total withholding taxes.
The company also pays all taxes on those shares which totaled up 282,500 shares where given out as part of there compensation plan!!
Now when you see this>>
PECORA ANDREW L
Director 1,330 Direct Acquisition (Non Open Market) at $2.34 per share. 3,112
This is where they where bought and PECORA ANDREW L
Director has bought continuously
The others where buying back in December of 2014
You just have to look for the price per share in the acquisition. If it says ""0"" that is what they paid! If it says ""2.40"" that is what they paid!
PECORA ANDREW L has been the only one constantly purchasing!
Caladrius' Investigational Targeted Cancer Immunotherapy For Late Stage Melanoma (5 minute)
Check out the new site!!
http://www.neostem.com/
Caladrius Biosciences, Inc. Finalizes Corporate Name Change From NeoStem, Inc.
Name Change Reflects Transformation Into Immunotherapy Company
June 08, 2015 06:00 ET | Source: Caladrius Biosciences, Inc.
NEW YORK, June 8, 2015 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq:CLBS) ("Caladrius" or the "Company"), a cell therapy leader with a late-stage clinical program for immuno-oncology, today announced the finalization of its corporate name change from NeoStem, Inc. to Caladrius.
"Coming on the heels of the recent $17.7 million grant awarded to us from the California Institute for Regenerative Medicine in support of our currently enrolling Phase 3 trial studying CLBS20, also known as NBS20, as a therapy for metastatic melanoma, our new identity as Caladrius Biosciences reflects our position as a leader in the innovation, development and manufacture of cell-based individualized medicine," said Dr. David J. Mazzo, Chief Executive Officer of Caladrius.
PCT (Progenitor Cell Therapy, LLC), a wholly-owned subsidiary of Caladrius and an industry-recognized single source premier cell therapy service provider, has been renamed "PCT, a Caladrius company" with no change to its focus on process development, engineering and manufacturing for clients across the cell therapy industry.
The product candidates in the Company's therapeutic pipeline will be referred to under new names:
• CLBS20, also known as NBS20, the Company's lead product candidate, currently enrolling in the Intus Phase 3 trial for the treatment of metastatic melanoma;
• CLBS10, formerly NBS10, an ischemic repair treatment of damaged heart muscle after acute myocardial infarction in late phase 2; and
• CLBS03, formerly NBS03D, which is poised to enter Phase 2 in a study for the preservation of beta cell function in adolescents with type 1 diabetes.
Caladrius remains listed on the NASDAQ stock exchange and now will trade under ticker symbol CLBS. The new website for Caladrius is www.caladrius.com; PCT, a Caladrius company, can be found on the web at www.pctcaladrius.com.
In Roman mythology, the Caladrius is a bird that visits the ill and is said to be able to absorb patients' illnesses and fly away, dispersing the illness and healing both itself and the patient. In that same spirit of recovery, Caladrius Biosciences is committed to its mission of bringing new, innovative and treatment paradigm-changing medical therapies to market, and in so doing, improving patients' lives and creating value for its shareholders.
About Caladrius Biosciences, Inc. (formerly NeoStem, Inc.)
Caladrius Biosciences, Inc. is among the first of a new breed of immunotherapy companies with proven expertise and unique experience in cell process optimization, development, and manufacturing. Caladrius is a cell therapy leader with late-stage clinical programs based on a proprietary platform technology for immuno-oncology, as well as additional platform technologies for ischemic repair and immunomodulation, and capabilities that support other cell therapy developers. This integrated approach supports the industry in bringing significant life-improving medical treatments to market. www.caladrius.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the timing and success of the proposed public offering. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include, among others, the uncertainties related to market conditions, the completion of the public offering on the anticipated terms or at all, the final terms of the proposed offering, and the satisfaction of customary closing conditions related to the proposed public offering. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see the factors described under the heading, "Item 1A. Risk Factors" in the Company's Annual Report on Form 10-K filed with the SEC on March 2, 2015 and those described in the Company's other periodic filings with the SEC. The Company undertakes no obligation to update or revise any forward-looking statements.
Caladrius Biosciences, Inc.
Eric Powers
Manager of Communications and Marketing
Phone: +1-212-584-4173
- See more at: http://globenewswire.com/news-release/2015/06/08/742728/10137619/en/Caladrius-Biosciences-Inc-Finalizes-Corporate-Name-Change-From-NeoStem-Inc.html?f=22&fvtc=7#sthash.Skmdu3Uu.dpuf
If it says NON OPEN MARKET and DIRECT it is not bought but given
You know I keep hearing about insider buying but can not find any other than a couple thousand share Petri gets as part of his pay!
All this is part of there pay or bonus program and is GIVEN to them, they are not purchases::
Click on the column header links to resort ascending (?) or descending (?).
Insider
Relation
Last Date ?
Transaction Type
OwnerType
Shares Traded
Last Price
Shares Held
PECORA ANDREW L Director 06/04/2015 Acquisition (Non Open Market) direct 1,330 2.3400 356,359
MAZZO DAVID J Officer 06/02/2015 Acquisition (Non Open Market) direct 80,000 239,543
TALAMO JOSEPH Officer 06/02/2015 Acquisition (Non Open Market) direct 22,500 30,839
VATERS ROBERT S Officer 06/02/2015 Acquisition (Non Open Market) direct 60,000 135,365
BERMAN RICHARD J Director 06/02/2015 Acquisition (Non Open Market) direct 10,000 0.0000 38,766
BERNSTEIN DREW Director 06/02/2015 Acquisition (Non Open Market) direct 10,000 0.0000 10,000
MYERS STEVEN S Director 06/02/2015 Acquisition (Non Open Market) direct 10,000 0.0000 152,931
KLOSK STEVEN M Director 06/02/2015 Acquisition (Non Open Market) direct 10,000 0.0000 32,000
TRABER PETER G Director 06/02/2015 Acquisition (Non Open Market) direct 10,000 0.0000 10,000
PECORA ANDREW L Director 06/02/2015 Acquisition (Non Open Market) direct 10,000 0.0000 355,029
WEI ERIC Director 06/02/2015 Acquisition (Non Open Market) indirect 10,000 0.0000 2,132,988
GREENACRE MARTYN D Director 06/02/2015 Acquisition (Non Open Market) direct 10,000 0.0000 88,531
SMITH ROBIN L Officer 06/02/2015 Acquisition (Non Open Market) direct 40,000 347,285
PECORA ANDREW L Director 05/21/2015 Acquisition (Non Open Market) direct 1,354 2.3000 345,029
PECORA ANDREW L Director 05/19/2015 Acquisition (Non Open Market) direct 925 0.0000 343,675
Read more: http://www.nasdaq.com/symbol/nbs/insider-trades#ixzz3cQ758I9N
Yes I read that article back in February when it was first posted by Andee, I also belong to SA. I realize the potential of this stock 3 years ago. The only problem I have ever had with it as soon as good news comes out the stock goes down? Yes eventually I hope it will rise, I have owned it 3 years now. They have a excellent pipeline of products and trails. New management seems to be getting the word out more. I do not even think a lot of people know old management is who bought this product! I have seen a lot of people make remarks about Robin but she is the one that got this deal. If you look at the charts you can see every time we took a step forward the pps went a step back/?? WHY??? Yes at this price it is a deal. When it was 50cents a share it was a deal, they did the reverse split to $5 a share and it was still a deal. The people who bought before the split bought at 50 cents there shares went with the 10 for 1 in the split so actually with all the good news over the last couple years there shares are worth 23 cents now ($2.34 after 10-1 split)
I believe in this company BUT can not understand the drop in price?? When we bought CSC at $5 a share we where in stage 2 of this trail. NBS I think was $7 a share then. Now we have gotten good results and are in stage 3 and the value has been cut more than half??? In this time we also have entered stage 2 of NBS10 with good results. You think somewhere a long the line the value would have held. We have lost 3/4 of the value during all this time! I think the company value should actually be more up around $10 a share now. SO YES IT IS A GOOD DEAL!
Here are the charts showing the down trend, I would actually like to know why???
Here is the 1 year chart, with all the good news, lower lows and lower highs all a long??? http://www.nasdaq.com/symbol/nbs/stock-chart
Here is the chart for 10 years with the splits marked. You can see what some people paid for this stock especially when you consider the splits! During this time we have had Robin come aboard(no arguments on of the top 25 stem cell people in the world), we have got PCT, we bought NBS20 from CSC a $5 value PPS in stage 2 now we are in stage 3(orphan drug status), we have started and finished stage 1 and are in stage 2 of NBS10 with good results. We have gotten many, many grants in this time. We now have new management! We are now valued a $2.27 a share??? OMG LOL YES IT IS A GOOD DEAL! http://www.nasdaq.com/symbol/nbs/stock-chart?intraday=off&timeframe=10y&splits=on&earnings=off&movingaverage=None&lowerstudy=volume&comparison=off&index=&drilldown=off
I have been with them about 3 years now and have hung on for a while! I meant the PPS would be good soon(probably a year or 2)
This will be a great stock some day soon!
They get money from PCT but I do not think in the near future it will be enough to finance trails! PCT is involved with KITE and JUNO!
If you go to this page http://www.neostem.com/investors/overview/ at the bottom you will find there presentation. Click to slide 4 it shows PCT then click slide 5 and it list some of the ""100"" clients they have! You will notice some big pharms in here! This is why it sort of surprises me that we have not partnered up! BUT also NBS said they would not partner if the offer was not good enough!
Big Pharms are getting into more stem cell trails so I suspect the clients will go up and profit also!
Biotech Stocks with Optimistic Trend – Plasmatech Biopharmaceuticals (PTBI), Prima Biomed (PBMD), NeoStem (NBS), Juno Therapeutics (JUNO)
http://www.wsobserver.com/biotech-stocks-with-optimistic-trend-plasmatech-biopharmaceuticals-ptbi-prima-biomed-pbmd-neostem-nbs-juno-therapeutics-juno/7217131/
OMG I HOPE YOUR RIGHT!! lol
I agree, I have been trying to tell people this and they think I don't know what I am talking about! If anyone of the newbees would do DD and read the charts it has happened for years with NBS! Eventually it will rise but I do not think it is going to be in the next couple months or so! For some reason the shorts have taken NBS down evrytime it has risen!
At this price it is a GREAT buy!
Caladrius Bioscience fits!!
Caladrius according to the Roman mythology, is a snow-white bird that lives in kings' houses. Supposedly, the bird refuses to look at any patient who is not going to make a full recovery.
It is said to also be able to take the sickness into itself and then fly away, dispersing the sickness and healing both itself and the sick person
NeoStem Announces Plans to Change Name to Caladrius Biosciences Reflecting Transformation Into Immunotherapy Company
NEW YORK, May 29, 2015 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a biopharmaceutical company developing novel cell-based individualized medicine therapies, today announced plans to change its corporate name to Caladrius Biosciences, Inc. ("Caladrius"), effective June 8, 2015.
A photo accompanying this release is available at http://www.globenewswire.com/newsroom/prs/?pkgid=33014
"The upcoming name change and rebranding of NeoStem are important steps to outwardly reflect what those in the industry and our clients already know about the company - that we are a leader in the innovation, development and manufacture of cell-based individualized medicine and immuno-oncology, with extensive experience in dozens of cell types as well as a pipeline using many cells of the immune system beyond stem cells," said Dr. David J. Mazzo, Chief Executive Officer of NeoStem. "The new corporate name reflects the company's integrated approach to cell therapy and creates a foundation for better market understanding of our position in the field."
PCT (Progenitor Cell Therapy , LLC), a wholly-owned subsidiary of NeoStem and an industry-recognized single source premier cell therapy service provider, will be renamed "PCT, a Caladrius company", also effective on June 8, with no change to its focus on process development, engineering and manufacturing for clients across the cell therapy industry.
In Roman mythology, the Caladrius is a bird that visits the ill and is said to be able to absorb patients' illnesses and fly away, dispersing the illness and healing both itself and the patient. In that same spirit of recovery, NeoStem is committed to pursuing the preservation and enhancement of human health though the development and manufacture of cell-based therapeutics that prevent, treat, or cure diseases by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. A new company logo will be introduced to reflect this change.
NeoStem's current therapeutic pipeline, for which new names for product candidates will be announced, includes:
• NBS20, the Company's lead product candidate, currently enrolling in the Intus Phase 3 trial for the treatment of metastatic melanoma, for which the first patient was randomized in April 2015;
• NBS10, for the treatment of damaged heart muscle after acute myocardial infarction, for which six and twelve month follow-up results have been announced; and
• NBS03D, which has been FDA-cleared for a Phase 2 study for the preservation of beta cell function in adolescents with type 1 diabetes.
Caladrius will trade on the NASDAQ stock exchange under ticker symbol CLBS beginning on June 8, 2015.
The new website for Caladrius will be www.Caladrius.com; PCT, a Caladrius company, will be found on the web at www.pctcaladrius.com.
About NeoStem, Inc. (Soon to be Caladrius Biosciences, Inc.)
NeoStem is a biopharmaceutical company pursuing the preservation and enhancement of human health globally through the development of novel cell-based individualized medicine therapeutics that prevent, treat or cure disease. The Company is developing therapies based on three platform technologies (immuno-oncology, ischemic repair and immunomodulation) with a focus on its lead, Phase 3 clinical program for NBS20 in immuno-oncology.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the timing and success of the proposed public offering. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include, among others, the uncertainties related to market conditions, the completion of the public offering on the anticipated terms or at all, the final terms of the proposed offering, and the satisfaction of customary closing conditions related to the proposed public offering. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see the factors described under the heading, "Item 1A. Risk Factors" in the Company's Annual Report on Form 10-K filed with the SEC on March 2, 2015 and those described in the Company's other periodic filings with the SEC. The Company undertakes no obligation to update or revise any forward-looking statements.
CONTACT: NeoStem, Inc.
Eric Powers
Manager of Communications and Marketing
Phone: +1-212-584-4173
Email: epowers@neostem.com
California Stem Cell Report
This blog provides news and commentary on public policy, business and economic issues related to the $3 billion California stem cell agency, officially known as the California Institute for Regenerative Medicine(CIRM). David Jensen, a retired California newsman, has published this blog since January 2005. His email address is djensen@californiastemcellreport.com.
Thursday, May 28, 2015
NeoStem Stock Price Falls 22 Percent as It Seeks to Match California Stem Cell Grant
NeoStem, Inc., has had a wild financial ride this past week with its stock price soaring and then plummeting in the wake of a nearly $18 million award last Thursday from the California stem cell agency.
The share price of the New York firm dropped 22 percent today after it announced that it was seeking to raise $25 million by selling 12.5 million shares. The move is aimed at helping to finance its stage three melanoma trial. Terms of the California award require a dollar-for-dollar match of the agency’s funds for the trial.
The market was not happy with the company’s plans to sell more of its stock at a possible price of $2.00 share. The stock today closed at $2.06. Last Thursday it closed at $2.95, up 28 percent for the day. Its 52-week performance has ranged from a low of $2.03 to a high of $7.23.
The Street web site today was critical of the firm, giving its stock a D-minus rating and recommended selling it. The Street said,
“This is driven by a number of negative factors, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income and generally disappointing historical performance in the stock itself."
Last week, some stem cell agency board members raised questions about the financing of the trial. Steve Juelsgaard, former executive vice president of Genentech, asked about the company’s “plan B.”
David Mazzo, NeoStem photo
David Mazzo, CEO of NeoStem, responded by mentioning a possible stock sale and also said the firm had a $30 million equity line of credit.
The company plans to conclude its stock sale on June 2. The stem cell award is on a fast-track to deliver cash to the company within 45 days of approval of the grant. But that requires evidence of the matching funds.
The prospectus for the offering says the four-year trial will cost $25 million, but one analyst says it could cost as up $51 million. The prospectus also indicated some of the money raised next week could go for purposes other than the melanoma trial.
http://californiastemcellreport.blogspot.com/2015/05/neostem-stock-price-falls-22-percent-as.html
I agree with you. This company is worth even more than $5 a share! PCT is worth that alone! When we bought CSC last year I believe we paid $5 a share for that((for those that don't know that is the cancer treatment in Phase 3))! Share where up to $7 afterwards and the shorts have drove the price down to around $2. I can not see it going down to much further but I said that at $4 and $3 also! This stock has solid science and eventually will be threw the roof!
A clinical research study to test a new patient-specific immunotherapy for men and women who have metastatic melanoma.
In case you know somebody in need!
http://theintusstudy.com/
Fighting cancer with innovative immunotherapy techniques
Business
By David J Mazzo, NeoStem | Thursday, April 2nd, 2015
http://www.theneweconomy.com/business/fighting-cancer-with-innovative-immunotherapy-techniques
I agree the company is worth a lot! I even said at the bottom of my post ""I post good and bad"". I have been invested in this company for years! Yes I myself have picked up ANOTHER lot of 2000 shares yesterday. As far as the analysts go, they actually have lowered there price in the last couple years. For those who have been in the stock awhile know this. It use to be the average analysts was around $28 a share. If you go back to the post here in January you will what you posted to me listed and posted by me I believe it will be higher BUT not in a year. In five years I believe it will be higher. Here is a chart of there PPS threw the years!
http://www.nasdaq.com/symbol/nbs/stock-chart?intraday=off&timeframe=10y&splits=off&earnings=off&movingaverage=None&lowerstudy=volume&comparison=off&index=&drilldown=off
Here is quotes for the last 10 years
When you get to this page select 10 years and scroll down!
http://www.nasdaq.com/symbol/nbs/historical
I am not downing this stock!! I was and am upset that every time they head up, they end up coming down!!
At the bottom of this page you can start reading my post with number #1650 in the search! Up in till a few days ago this board was mostly me posting articles you do not see any where else! I do my DD and post it here for others! I spend at least 1 to 2 hours a day looking for news on NBS!